Oubari Pharma

Oubari Pharma, established in 1989, holds the distinction of being Syria's inaugural pharmaceutical company specializing in sterile liquid injection products. The firm has successfully developed a diverse portfolio of licensed medications through strategic collaborations with prominent global pharmaceutical entities. Oubari Pharma is dedicated to ongoing product innovation, driven by a keen identification of regional market demands. This commitment ensures the provision of high-quality pharmaceutical solutions offered at competitive price points, addressing critical healthcare needs within its operational scope. Adherence to stringent Good Manufacturing Practices (GMP) and multiple ISO certifications underscores Oubari Pharma's unwavering commitment to reliability across all facets of its pharmaceutical production processes. The company's product catalog features essential medications such as Diclofenac Oubari and Amlodipine Oubari, designed to meet varied therapeutic requirements. With a workforce of 500-1,000 employees, Oubari Pharma leverages its operational expertise and team capabilities to maintain these high standards. Meet Oubari Pharma's team to understand the dedication behind their quality-driven manufacturing. Operating within the Pharmaceuticals and Healthcare sectors, Oubari Pharma generates approximately $100.0M in revenue. Its strategic focus on identifying regional market needs and delivering quality products positions it effectively within its geographic and industry segments. The company's operational footprint is centered in Syria, with a single primary location, serving markets across Asia and the Middle East, as indicated by its product development and market focus. The company's history and product development strategy highlight its role in advancing pharmaceutical availability and quality in its region.